Physician profile
Jeffrey L Stein
NPI 1053485318
$6,513.00
in general payments reported to CMS, 2019-2025
39 companies · $446 in 2025
The $446 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $924 · 2020: $1,009 · 2021: $1,757 · 2022: $775 · 2023: $953 · 2024: $650 · 2025: $446.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,049.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,048.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,382.45 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Abbvie INC. | $685.93 | 2021-2025 | Vraylar, Ubrelvy |
| Amarin Pharma, INC. | $364.24 | 2019-2022 | |
| Glaxosmithkline, LLC. | $340.19 | 2020-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Exact Sciences Corporation | $337.17 | 2023-2025 | Cologuard Collection Kit |
| Lilly USA, LLC | $266.75 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Pfizer INC. | $266.62 | 2020-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $256.52 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $251.30 | 2019-2025 | Jardiance |
| Novo Nordisk INC | $247.95 | 2019-2025 | Ozempic |
| Allergan, INC. | $223.04 | 2019-2021 | |
| Eisai INC. | $214.29 | 2020-2022 | |
| Novartis Pharmaceuticals Corporation | $154.88 | 2021-2024 | |
| Janssen Pharmaceuticals, INC | $142.16 | 2019-2022 | |
| Esperion Therapeutics, INC. | $133.56 | 2020-2024 | Nexletol |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Stein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.